TABLE III.
Concurrent chemoradiotherapy in locally advanced (labc) or inflammatory breast cancer
| Reference | Disease stage | Chemotherapy | Pts (n) | rt dose (Gy) | Toxicity | Outcome |
|---|---|---|---|---|---|---|
| Kosma et al., 199753 | ulabc failed first-line chemotherapy | 5fu 500 mg/m2 twice weekly | 17 | 75–90 (4–5 twice weekly) | Grade 2 rt pneumonitis: 1 Grade 2 skin toxicity: 2 |
cr in 5; 3 underwent mastectomy with all 3 experiencing a pcr |
| Skinner et al., 200055 | iib–iii | Paclitaxel (30 mg/ m2) twice weekly for 8 weeks | 29 | 45 | Surgical complications: 41% | Response rate: 89% |
| Formenti et al., 200347 | iib–iii | Paclitaxel 30 mg/ m2 twice weekly | 44 | 45 plus 18 | Grade 3 skin toxicity: 7% | cr: 16% |
| Kao et al., 200548 | ulabc (iiib–c) | Bolus infusion vinorelbine (20 mg/ m2 day 1) plus continuous infusion (20–30 mg/ m2 daily×4 days) | 16 | 60 | Moist desquamation: 8 | pcr in 7 of 15 |
| Bollet et al., 200652 | ii–iii | 5fu 500 mg/ m2 daily days 1–5, and vinorelbine 25 mg/ m2 days 1 and 6 | 60 | 50 | Grade 4 hematologic: 22% | pcr in 27% |
| Gaui et al., 200754 | ulabc failed first-line chemotherapy | Capecitabine 850 mg/ m2 for 14 days | 28 | 50 | Grades 3–4: none | pcr in 1; 82% became operable |
| Chakravarthy et al., 200650 | ii–iii | Paclitaxel 30 mg/ m2 twice weekly | 38 | 45 plus 14 | Skin toxicity: 1 | pcr in 13 (34%) |
| Adams et al., 201014 | iib–iii | Paclitaxel 30 mg/ m2 twice weekly | 105 | 45 plus 14 | na | Pathologic response in 34% |
Pts = patients; rt = radiotherapy; ulabc = unresectable labc; 5fu = 5-fluorouracil; cr = complete response; pcr = pathologic complete response; na = not available.